Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
10 stopped studies mapped to Malignant Histiocytic and Dendritic Cell Neoplasm and descendants · 100% state a reason
Over the 10 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03316573 | Pembrolizumab in Neoplasms or Lymphomas | Phase 2 | suspended | Oct 20, 2017 | Dana-Farber Cancer Institute | Low accrual | Enrollment / accrual |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid… | Phase 2 | terminated | Jan 19, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04317781 | Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After… | Phase 2 | terminated | Mar 23, 2020 | M.D. Anderson Cancer Center | The protocol was terminated early due to slow participant accrual and the sponsor not willing to… | Enrollment / accrual |
| NCT04109482 | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. | Phase 1 / Phase 2 | terminated | Sep 30, 2019 | Mustang Bio | Business reasons. | Sponsor / business decision |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell… | — | terminated | Dec 9, 2022 | Mustang Bio | Business Reasons | Sponsor / business decision |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT03203369 | Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN(ABC123) | Phase 1 | terminated | Jun 29, 2017 | Cellectis S.A. | The trial was discontinued due to sponsor's decision and not a consequence of any safety concern. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials